Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of stapokibart in prurigo nodularis
CTR20241776Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in prurigo nodularis (PN), sponsored by Keymed Biosciences. Started May 2024; status: completed.
02
Drugs
stapokibart
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20241776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241776.